Group items tagged

The major players in the market include Oracle Corporation (U.S), Medidata Solutions, Inc. (U.S), BioClinica, Inc. (U.S), OmniComm Systems, Inc. (U.S), PAREXEL International Corp. (U.S), DATATRAK International, Inc. (U.S), AG Mednet, Inc. (U.S), Merge Healthcare Incorporated (U.S), PHT Corporation (U.S), eResearch Technology, Inc. (U.S), and CRF Health (U.S).

The major players in the market include Oracle Corporation (U.S), Medidata Solutions, Inc. (U.S), BioClinica, Inc. (U.S), OmniComm Systems, Inc. (U.S), PAREXEL International Corp. (U.S), DATATRAK International, Inc. (U.S), AG Mednet, Inc. (U.S), Merge Healthcare Incorporated (U.S), PHT Corporation (U.S), eResearch Technology, Inc. (U.S), and CRF Health (U.S).

The infection control market research reports suggest increased demand of disinfection products due to rise in surgical proceedings, chronic diseases, and increased number of aging population.

Nerve repair market will grow at steady CAGR. Increasing aging population, chronic diseases and awareness will be the key drivers for the global industry.

As of 2015, General Electric Company (U.S.) and Vital Images, Inc. (U.S.) [now part of Toshiba Corporation (Japan)] are estimated to hold the leadership position in the global market. Other key players in this market include Agfa-Gevaert N.V. (Belgium), Carestream Health, Inc. (U.S.), FUJIFILM Holdings Corporation (Japan), Koninklijke Philips N.V. (Netherlands), Qi Imaging (U.S.), Siemens AG (Germany), TeraRecon, Inc. (U.S.), and Visage Imaging, Inc. (U.S.), among others. Market players primarily focus on the development of innovative AV software, geographic expansion, and strategic acquisitions as key strategies to ensure their growth in the advanced visualization market.

As of 2014, Agilent Technologies, Inc. (U.S.) held the leadership position in the global market. Over the past three years, the company adopted new product launches and strategic acquisitions as its key business strategies to ensure its dominant position in this market. In addition, TE Connectivity Ltd. (Switzerland), Danaher Corporation (U.S.), E.S.I. Environment Sensors Inc. (Canada), Honeywell International, Inc. (U.S.), Lockheed Martin Corporation (U.S.), Ball Aerospace and Technologies Corporation (U.S.), The Raytheon Company (U.S.), Siemens AG (Germany), and Thales Group (France) are some of the other key players in this market.

The top leaders in catheter stabilization device market include Medtronic plc (U.S.), 3M Company (U.S.), C. R. Bard, Inc. (U.S.), Baxter International, Inc. (U.S.) , B. Braun Melsungen AG (Germany), ConvaTec Inc. (U.S.), Merit Medical Systems, Inc. (U.S.), Smiths Group plc (U.K.), Centurion Medical Products (U.S.), and M.C. Johnson Company, Inc. (U.S.).

Diets to lose belly fat can be disappointing, especially when they expect you to live off two peas and pod for the day. However, the 7 Day Belly Blast Diet plan actually encourages you to eat and melts away the stubborn belly fat by combining certain foods together for a synergistic approach to eliminate fat. Eat as much and as often as you like, just be sure you are eating the right foods to lose belly fat fast. The 7 Day Belly Blast Diet works for everybody, regardless of size, age or gender. The key to success is the proven meals and snacks that boost's the body's metabolism to realize rapid results, while reducing the fat promoting cortisol stored in the stomach caused by stress. The best way to lose belly fat fast is by eating whole foods and steering clear from chemical supplements that can cause more body damage than the fat. By learning a new way to control your belly fat, you can enjoy a few treats on the holidays and get rid of the belly fat instantly using the Belly Blast Diet techniques.

I'm a busy mom on the go with two rambunctious boys aged three and five, and just found the answer to keeping their meals safe and secure in their bowls. My friend recommended this anti-gravity, no-spill bowl for youngsters, so I checked out the Gyro Bowl reviews, liked what I read, and bought four bowls.

Market Overview: Next-generation antibody therapeutics includes the use of new improvised therapeutic antibody to form innovative medicines for treating various diseases. Next-generation antibody therapeutics is developed clinically by pharmaceutical and biotechnology companies for several diseases. The Next Generation Antibody Therapeutics Market size was worth $ XX million in 2018 and is forecasted to reach $ XX million by 2026, expected to grow at a high CAGR during the forecast period 2019-2026. Market Dynamics: The Next Generation Antibody Therapeutics Market is growing due to several factors such as rising incidence of chronic diseases, increasing emergence of antibody technology, new drug discovery, large number of government initiatives, and growing research and development activities for new therapies. Rising prevalence of chronic disease such as cancer, asthma, diabetes and COPD are boosting the growth of the next generation antibody therapeutics market. For instance, according to National Cancer Institute in 2018, in United States, an estimated 1,735,350 new cases of cancer will be diagnosed and 609,640 people will die from the disease. The development of next-generation monoclonal antibodies has expanded beyond oncology into all therapeutic areas. For instance, ADCs were initially focused primarily on cancer, but Genentech has applied to infectious diseases, leading to the discovery and development of THIOMAB antibiotic conjugates (TACs) for the treatment of methicillin-resistant Staphylococcus aureus (MRSA). The technological advancements in antibody therapeutics have led to the development of more efficient antibody therapeutics, hence, driving the growth in the next-generation antibody therapeutics market. However, stringent government regulation, high cost and time required for research and development activities are some of the factors hindering the growth for global next-generation antibody therapeutics market. Market Segmentation: Based o

Market Overview: Skin substitutes are natural, synthetic or biosynthetic materials, used to cover large wounds to restore at least some of the functions of the skin. Skin substitutes provides temporary or permanent wound closure and protect the wound from infection, further damage and water loss, and reduce pain. They also facilitate the growth of the normal skin over the wound. Skin substitutes provide a permanent solution and are used in the treatment of conditions like burns, trauma wounds, diabetes or venous ulcers, where skin grafts may not be possible. Market Dynamics: Rising chronic skin diseases is expected to drive the skin substitutes market. For instance, according to the global burden of disease study 2013, Skin conditions contributed around 1.79% to the global disease burden. According to the World Health Organization, about 132,000 melanoma skin cancers occur each year worldwide. Thus, the rising chronic diseases is increasing the demand for skin substitutes in the forecast period. Rising prevalence of diabetes is expected to boost the market. This is owing to the risk of developing a diabetic foot ulcer over the period of time in diabetic patients. For instance, WHO has reported that the incidence of diabetes for all age-groups worldwide was estimated to be 2.8% in 2000 and 4.4% in 2030. The total number of people with diabetes is anticipated to rise from 171 million in 2000 to 366 million in 2030. Thus, as a consequence, the prevalence of diabetes related complications are expected to increase over the forecast period. There are several limitations to the commercially available skin substitutes, like reduced vascularization, poor mechanical integrity, failure to integrate, scarring, and immune rejection. Market Segmentation: Rise in preference for acellular skin substitutes to implant-based skin surgery is expected to drive the growth of the skin substitutes market. For instance, the American Society of Plastic Surgeons in 2012, reported that

Body dysmorphic disorder (BDD), or body dysmorphia, is a mental health condition where a person spends a lot of time worrying about flaws in their appearance. These flaws are often unnoticeable to others. People of any age can have BDD, but it's most common in teenagers and young adults. It affects both men and women.

The Hartford Foundation supports multiple projects focused on improving care transitions, which are critical for frail, elderly patients seeing multiple providers in different settings.The foundation is especially concerned with improving care for older adults with multiple chronic conditions and functional impairment.